Grace Therapeutics Financial Results
Grace Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $2.1 million. The company is currently focused on resubmitting its New Drug Application (NDA) for GTx-104 after addressing CMC and non-clinical items identified by the FDA. Management noted that a recent $10 million financing has extended the company's cash runway through the end of 2028.
“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104.”
Prashant Kohli, Chief Executive Officer
“The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission.”
Prashant Kohli, Chief Executive Officer